Recurrence of drug-induced reactions in DRESS patients
Background Drug reaction with eosinophilia and systemic symptoms (DRESS) may relapse following introduction of drugs structurally unrelated to the initial culprit drug. Objective To assess the frequency and characteristics of recurrent drug eruptions in patients with history of DRESS. Methods Patien...
Saved in:
Published in | Journal of the European Academy of Dermatology and Venereology Vol. 29; no. 4; pp. 801 - 804 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.04.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Drug reaction with eosinophilia and systemic symptoms (DRESS) may relapse following introduction of drugs structurally unrelated to the initial culprit drug.
Objective
To assess the frequency and characteristics of recurrent drug eruptions in patients with history of DRESS.
Methods
Patients who had developed adverse cutaneous reaction after DRESS occurrence were recruited from the regional database of Upper Normandy in France. Rate of recurrences were compared with patients with Toxic Epidermal Necrolysis (TEN) and Stevens–Johnson syndrome (SJS) patients during the same time frame.
Results
Of the 60 cases of DRESS collected, 15 (25%) with recurrences were retained for analysis. Seven patients had a single recurrence, whereas eight patients had several relapses. In the patients with pre‐existing DRESS, recurrences were incomplete, corresponding to cutaneous rash in 13 cases and associated with eosinophilia in seven cases. Internal organ involvement was observed in two cases. In contrast, a single recurrence was found out of 61 patients with TEN/SJS.
Conclusion
Incomplete recurrences with structurally unrelated culprit drugs are a frequent phenomenon in DRESS patients. |
---|---|
Bibliography: | ArticleID:JDV12419 istex:9262ABE7BD27CF2EBE750424B8B0C7BB13927C04 ark:/67375/WNG-5B5T5DW5-4 Funding sources D. Picard is an employee of Novartis. M. Vellar is an employee of Servier. P. Musette is consultant for Galderma and Servier. Conflict of interest None declared. |
ISSN: | 0926-9959 1468-3083 |
DOI: | 10.1111/jdv.12419 |